Cargando…

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-reco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kansara, Abhishek, Mubeen, Faiza, Shakil, Jawairia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Houston Methodist DeBakey Heart & Vascular Center 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461689/ https://www.ncbi.nlm.nih.gov/pubmed/36132575 http://dx.doi.org/10.14797/mdcvj.1120

Ejemplares similares

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
por: Mende, Christian W.
Publicado: (2021)

FRI093 Severe Hypertriglyceridemia Post Liver Transplant- A Multifactorial Disorder
por: Saand, Aisha R, et al.
Publicado: (2023)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
por: De Nicola, Luca, et al.
Publicado: (2022)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
por: Klen, Jasna, et al.
Publicado: (2023)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?
por: Staessen, Jan A., et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Li, Ning, et al.
Publicado: (2021)

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
por: Shuster, Shirley, et al.
Publicado: (2021)

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
por: Vasquez-Rios, George, et al.
Publicado: (2020)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
por: Tsai, Kai-Fan, et al.
Publicado: (2021)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
por: Keller, Daria M., et al.
Publicado: (2022)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 Inhibitors in Chronic Kidney Disease
por: Nakagawa, Takahiko, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
por: Kovesdy, Csaba, et al.
Publicado: (2022)

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Ul Amin, Noor, et al.
Publicado: (2022)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
por: Clemmer, John S., et al.
Publicado: (2023)

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
por: Miyamoto, Yasunori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7bbb2n5klqfmdn9srd28md08p8